Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc. (ORMP)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Oramed has transitioned from a clinical-stage biopharmaceutical company to a strategic healthcare operating company. Following the March 2026 closing of the "Lifeward Transaction," Oramed transferred its POD™ oral insulin technology to OraTech Pharmaceuticals Ltd. (a subsidiary of Lifeward) and no longer conducts direct clinical development. The company now focuses on active ownership of a portfolio of investments, including significant stakes in Alpha Tau Medical Ltd. and Lifeward Ltd., alongside real estate and private credit investments.
Key Financial Metrics
| Metric (in thousands, except per share) | Six Months Ended June 30, 2026 | Three Months Ended June 30, 2026 | Dec 31, 2025 (Balance Sheet) |
|---|---|---|---|
| Revenues | $0 | $0 | N/A |
| Operating Loss | $(6,425) | $(2,766) | N/A |
| Financial Income, Net | $148,592 | $103,743 | N/A |
| Net Income | $116,466 | $78,156 | N/A |
| Diluted EPS | $2.76 | $1.84 | N/A |
| Cash and Cash Equivalents | $15,245 | N/A | $45,947 |
| Total Assets | $369,643 | N/A | $230,864 |
| Total Liabilities | $52,170 | N/A | $31,120 |
| Stockholders' Equity | $317,473 | N/A | $199,744 |
Material Changes vs. Prior Period
- Profitability Surge: Net income for the six months ended June 30, 2026, was $116.5 million, a massive increase from $5.6 million in the same period in 2025. This was driven primarily by a $133.4 million unrealized gain on the revaluation of the investment in Alpha Tau Medical Ltd.
- Revenue Cessation: Operating revenues dropped to zero from $2.0 million in the prior year period, as the company has no remaining performance obligations under previous license agreements (e.g., HTIT) and has divested its core IP.
- Investment Portfolio Growth: Total assets increased by approximately $138.8 million year-over-year, largely due to the fair value appreciation of investments in Alpha Tau (shares and warrants) and the addition of the Lifeward investment portfolio.
- Cash Position: Cash and cash equivalents decreased by $30.7 million to $15.2 million, primarily due to dividend payments ($10.4 million), investments in marketable securities and private credit, and the funding of the Lifeward transaction.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management views the company as a strategic operating entity focused on value creation through active ownership. The company expects to maintain current planned activities for at least the next 12 months based on current cash resources. Future growth is anticipated through the appreciation of portfolio companies (Alpha Tau, Lifeward) and returns from real estate and private credit investments.
Key Risks and Contingencies:
- Investment Volatility: A significant portion of net income is derived from unrealized gains on fair value measurements of investments (Alpha Tau, Lifeward, Scilex). These values are subject to market fluctuations and may not be realized in cash.
- Scilex Repayment Risk: Oramed holds significant notes and warrants in Scilex Holding Company. As of August 10, 2026, Scilex had not made a scheduled $5.0 million payment due July 31, 2026. Failure to pay by September 30, 2026, could result in the obligation being satisfied via equity delivery.
- Lifeward Transaction Dependencies: The value of the Lifeward investment is tied to the performance of Lifeward's ReWalk exoskeleton sales and the success of the transferred oral insulin program managed by OraTech.
- Geopolitical Risk: Operations in Israel expose the company to political, economic, and military risks, though management currently sees no immediate risk to operations.
Investor Verification Checklist
- Alpha Tau Valuation: Verify the current market price of Alpha Tau shares and the methodology used for the $133.4 million unrealized gain, which drove the majority of the period's net income.
- Scilex Default Status: Confirm whether Scilex has met its September 30, 2026, payment deadline for the outstanding obligations (~$36 million total) or if the debt has been converted to equity.
- Liquidity Runway: Assess the $15.2 million cash balance against upcoming commitments, including the potential $9 million "Additional Note" funding for Lifeward if specific sales or stock price triggers are met.
- Dividend Sustainability: Review the $10.4 million dividend paid in the period and determine if future distributions are sustainable given the lack of operating revenue.
- Real Estate Exposure: Evaluate the fair value assumptions for the Hapisga loan ($38.4 million) and other real estate loans, which are measured at fair value and subject to market conditions.